AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

In 2019 it formed a partnership with AstraZeneca and will co-develop and co-commercialize Enhertu and Datroway, its two leading assets from its ADC platform. In 2023, it formed another partnership ...

The VENTANA TROP2 device aims to help identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Trop2-directed antibody drug conjugate, Datroway’s (datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug conjugate (ADC) for breast cancer, Datroway, the latest to emerge from ...

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

That same month, Datroway was granted priority review by the FDA for EGFR-mutated NSCLC—which analysts have described as the larger market opportunity, with a potential approval decision ...